Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx®-Melanoma and Clinicopathologic Factors Provides Optimized, Personalized Survival Prognoses for Patients with Cutaneous Melanoma

FRIENDSWOOD, Texas–(BUSINESS WIRE)—- $CSTL #CSTL–Castle announced the publication of a study validating the performance of DecisionDx®-Melanoma’s proprietary algorithm, i31-ROR.
Click here to view original post